AI assistant
PERCHERON THERAPEUTICS LIMITED — Capital/Financing Update 2018
Mar 27, 2018
65543_rns_2018-03-27_81836ab9-8bd7-43e6-bfc4-bcbea928e4fd.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
MARKET RELEASE
28 March 2018
Antisense Therapeutics Limited
TRADING HALT
The securities of Antisense Therapeutics Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Tuesday, 3 April 2018 or when the announcement is released to the market.
Security Code: ANP
Dean Litis
PRINCIPAL ADVISER, LISTINGS COMPLIANCE (MELBOURNE)
ASX Compliance Pty Limited ABN 26 087 780 489
20 Bridge Street Sydney NSW 2000
www.asx.com.au Customer service 13 12 79
==> picture [164 x 53] intentionally omitted <==
Wednesday 28 March 2018
Dean Litis Principal Adviser Listings Compliance (Melbourne) ASX Compliance Pty Limited
Email: [email protected]
Dear Dean,
Request for Trading Halt for Antisense Therapeutics Limited
In accordance with ASX Listing Rule 17.1, the Directors of Antisense Therapeutics Limited (“the Company”) request an immediate trading halt in respect of its securities (ASX Code: ANP).
In requesting the trading halt, the Company provides the following information:
-
The trading halt is requested pending an institutional placement and entitlement issue;
-
Unless otherwise requested by the Company, the Company requests the trading halt to remain in place until the earlier of the release of an announcement to the market or the morning of Tuesday 3[rd] April 2018; and
-
The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.
Yours sincerely,
==> picture [67 x 49] intentionally omitted <==
Phillip Hains Company Secretary
6-8 Wallace Avenue Toorak, Victoria Australia 3142
Phone: + 61 (0)3 9827 8999 Facsimile: + 61 (0)3 9827 1166
Antisense Therapeutics Limited ABN 41 095 060 745